glp-1 hype Beyond the Hype: Where and how Digital Health Founders Should Build in the Market GLP-1 Agonists: The Pros and

The positive reviews cluster around a few themes

In fact, such a design incorporates substantial uncertainty if background therapy, population risk, or adherence differs significantly from historical trials, especially in view of the rapidly changing scenario of T2D management with a treat-to-benefit approach

Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1) Proceedings of the National Academy of Sciences of the United States of America

Update on FDAs ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity: Preliminary evaluation does not suggest a causal link [Drug Safety Communication]

As we navigate this danger zone in weight loss management with GLP-1 agonists, history offers valuable lessons

Veterans cohort, for instance, sodium-glucose cotransporter 2 (SGLT2) inhibitors were found to be associated with a higher rate of peripheral artery disease-related surgical events than DPP-4 inhibitors (11.2 vs